Open Orphan PLC New Contract with SFA Therapeutics (2351X)
18 December 2019 - 6:00PM
UK Regulatory
TIDMORPH
RNS Number : 2351X
Open Orphan PLC
18 December 2019
18 December 2019
Open Orphan plc
("Open Orphan" or the "Company")
New Contract with SFA Therapeutics
Open Orphan, a European-focussed, rare and orphan drug
consulting services platform, is pleased to announce the signing of
a contract with SFA Therapeutics, a biopharmaceutical company based
in Pennsylvania, USA ("SFA Therapeutics").
This contract sees Venn Life Sciences ("Venn"), part of Open
Orphan plc, provide SFA Therapeutics with assistance in the filing
of a European Medicines Agency application for Orphan Drug
Designation including providing both consulting and regulatory
writing services. Open Orphan is delighted to support SFA
Therapeutics in the development of its promising novel treatment
and it is hoped that this agreement will be the first step in a
longer-term relationship between both companies.
The contract is evidence of Open Orphan executing upon its
strategy of winning contracts in the fast-growing orphan drug
sector and its capability in being able to assist North American
companies with their European activities. It is also an important
contract as it is the first time that Venn has utilised Open
Orphan's skills and expertise in filing a European Medicines Agency
Orphan Drug Designation for a North American company which already
has a US FDA Orphan Drug Designation.
Cathal Friel, Chief Executive of Open Orphan commented:
"This contract is a further demonstration of delivery against
one of Open Orphan's key objectives, transforming Venn. The
contract is an exciting one as we are now building on our
capability by actively winning work in the fast-growing orphan drug
sector. We look forward to delivering the contract for SFA
Therapeutics and building upon the relationship."
Enquiries:
Open Orphan plc Tel: +353 1 644 0007
Cathal Friel, Chief Executive Officer
Arden Partners (Nominated Adviser and Joint Broker) Tel: +44
(0)20 7614 5900
John Llewellyn-Lloyd / Ruari McGirr / Benjamin Cryer
Davy (Euronext Growth Adviser and Joint Broker) Tel: +353 (0)1
679 6363
Anthony Farrell (Corporate Finance)
Camarco (Financial PR) Tel: +44 (0)20 3757 4980
Tom Huddart / Dan Sherwen
Notes to Editors on Open Orphan:
Open Orphan plc is a European-focused, rare and orphan drug
consulting services platform. The Company intends to roll up a
number of orphan drug services businesses. Open Orphan has two data
driven digital platforms, a Genomic Health Data Platform, which is
establishing a rare disease database and a Virtual Rep platform
enabling pharmaceutical companies to engage key opinion leaders and
physicians. The Company is targeting rapid growth in one of the
fastest growing sectors in the global pharmaceutical industry
targeting under-supplied treatment for life threatening or very
serious diseases and rare disorders.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
CNTEAPAXFDANFFF
(END) Dow Jones Newswires
December 18, 2019 02:00 ET (07:00 GMT)
Hvivo (LSE:HVO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hvivo (LSE:HVO)
Historical Stock Chart
From Jul 2023 to Jul 2024